Trovagene Inc (NASDAQ:TROV) Shorts Declined By 2.82%

June 27, 2018 - By Sarah Holford

TrovaGene, Inc. (NASDAQ:TROV) Corporate Logo

Big Money Sentiment increased to 0.75 in Q1 2018. It has change of 0.22, from 2017Q4’s 0.53. The ratio is positive due to TrovaGene, Inc. positioning: 4 sold and 8 reduced. 7 funds amassed holdings and 2 increased holdings. Investors holded 2.44 million in 2017Q4 but now own 2.63 million shares or 7.88% more.
Bancorp Of Montreal Can invested 0% of its capital in TrovaGene, Inc. (NASDAQ:TROV). Bnp Paribas Arbitrage stated it has 0% of its capital in TrovaGene, Inc. (NASDAQ:TROV). Cwm Limited Liability Com reported 1,000 shs. Barclays Public Ltd Company has 25,000 shs for 0% of their capital. Northwestern Mutual Wealth Management Company has invested 0% in TrovaGene, Inc. (NASDAQ:TROV). Moreover, Susquehanna International Grp Llp has 0% invested in TrovaGene, Inc. (NASDAQ:TROV). Messner And Smith Theme Value Investment Mgmt Ca has 0.01% invested in TrovaGene, Inc. (NASDAQ:TROV) for 22,850 shs. Blackrock accumulated 398,693 shs or 0% of the stock. Meeder Asset Mgmt Incorporated invested 0% of its capital in TrovaGene, Inc. (NASDAQ:TROV). Carroll Associates reported 1,500 shs stake. Geode Mngmt Ltd Llc holds 0% or 139,330 shs in its capital. Moreover, Renaissance Tech Limited Liability Corp has 0% invested in TrovaGene, Inc. (NASDAQ:TROV) for 128,671 shs. State Street reported 13,300 shs. Deutsche Financial Bank Ag holds 0% of its capital in TrovaGene, Inc. (NASDAQ:TROV) for 71 shs. Polaris Greystone Finance Group Incorporated Ltd Llc invested in 0% or 12,000 shs.

Change of 2.82% for Trovagene Inc (NASDAQ:TROV)’s shorted shares was recorded. FINRA issued shorted shares of TROV’s total 4.93 million shares. The 5.07M previous shares are down with 2.82%. With Average volume 1.39M, TROV’s previous position will take 4 days to recover. Trovagene Inc float short is 13.35%.

TROV reached $0.801 during the last trading session after $0.019 change.TrovaGene, Inc. has volume of 352,784 shares. Since June 27, 2017 TROV has declined 63.33% and is downtrending. TROV underperformed the S&P500 by 75.90%.

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the United States.The firm is valued at $3.96 million. The firm intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor circulating tumor DNA using urine or blood samples.Last it reported negative earnings. It offers Precision Cancer Monitoring (PCM) platform, which provides cancer monitoring by tracking and quantifying levels of ctDNA from either urine or blood samples, as well as intends to offer clinical information beyond the current standard of care.

TrovaGene, Inc. (NASDAQ:TROV) Ratings Coverage

In total 2 analysts cover TrovaGene (NASDAQ:TROV). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:TROV) has 100% bullish analysts. With $700 highest and $1.0 lowest price target, TrovaGene has $2.50 average price target or 212.11% above the current ($0.801) price. 5 are the (NASDAQ:TROV)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Friday, June 15 Maxim Group upgraded the shares of TROV in report to “Buy” rating. On Tuesday, March 6 the firm has “Buy” rating by H.C. Wainwright given. In Monday, June 4 report H.C. Wainwright maintained it with “Buy” rating and $700 target. The stock rating was maintained by H.C. Wainwright with “Buy” on Monday, June 11. On Tuesday, June 19 the stock of TrovaGene, Inc. (NASDAQ:TROV) has “Buy” rating given by H.C. Wainwright.

Another two news for TrovaGene, Inc. (NASDAQ:TROV) were briefly released by: Seekingalpha.com on June 08, 2018 with title “Trovagene announces pricing of $18M public offering; shares down 58% premarket”. The other Streetinsider.com‘s article was titled “Trovagene (TROV) Announces Preliminary Data from First Dosing Cohort Demonstrating Durable Treatment Effect of …” and released on June 27, 2018.

TrovaGene, Inc. (NASDAQ:TROV) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.